Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2020 Jan 16. pii: S0923-7534(20)35926-3. doi: 10.1016/j.annonc.2019.12.009. [Epub ahead of print]

PMID:
32085891
2.

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Schmid S, Früh M, Peters S.

Lancet Oncol. 2020 Feb 3. pii: S1470-2045(19)30859-9. doi: 10.1016/S1470-2045(19)30859-9. [Epub ahead of print] No abstract available.

PMID:
32027845
3.

Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland.

Schmid S, Suipyte J, Herrmann C, Mousavi M, Hitz F, Früh M.

Eur J Cancer Care (Engl). 2020 Jan 21:e13206. doi: 10.1111/ecc.13206. [Epub ahead of print]

PMID:
31965647
4.

Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.

Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R.

J Thorac Oncol. 2020 Mar;15(3):416-425. doi: 10.1016/j.jtho.2019.11.023. Epub 2019 Dec 5.

PMID:
31812754
5.

Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77].

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Dec;141:332. doi: 10.1016/j.radonc.2019.10.006. No abstract available.

PMID:
31810511
6.

Coverage rates and timeliness of nationally recommended vaccinations in Swiss preschool children: A descriptive analysis using claims data.

Schneider R, Reinau D, Schur N, Blozik E, Früh M, Signorell A, Heininger U, Schwenkglenks M, Meier CR.

Vaccine. 2020 Feb 5;38(6):1551-1558. doi: 10.1016/j.vaccine.2019.11.057. Epub 2019 Nov 30.

PMID:
31791812
7.

Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.

Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M.

Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.

PMID:
31745593
8.

Drug prescription patterns, polypharmacy and potentially inappropriate medication in Swiss nursing homes: a descriptive analysis based on claims data.

Schneider R, Reinau D, Schur N, Blozik E, Früh M, Signorell A, Meier CR, Schwenkglenks M.

Swiss Med Wkly. 2019 Sep 30;149:w20126. doi: 10.4414/smw.2019.20126. eCollection 2019 Sep 23.

9.

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.

Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E.

Noncoding RNA. 2019 Jun 17;5(2). pii: E41. doi: 10.3390/ncrna5020041.

10.

EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer.

Früh M, Peters S.

Ann Oncol. 2019 Aug 1;30(8):1190-1192. doi: 10.1093/annonc/mdz185. No abstract available.

PMID:
31198952
11.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
12.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402. Erratum in: JAMA Oncol. 2019 Jul 1;5(7):1070.

13.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15. Erratum in: Radiother Oncol. 2019 Dec;141:332.

PMID:
31015173
14.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
15.

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.

Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M.

Lung Cancer. 2019 Apr;130:149-155. doi: 10.1016/j.lungcan.2019.02.020. Epub 2019 Feb 19.

PMID:
30885336
16.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H.

Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.

PMID:
30765392
17.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.

J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.

18.

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.

Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, Wälti T, Thürlimann B, Früh M, Driessen C, Joerger M.

Cancer Chemother Pharmacol. 2019 Apr;83(4):763-774. doi: 10.1007/s00280-019-03783-9. Epub 2019 Jan 25.

PMID:
30684020
19.

Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys.

Mousavi SM, Schmid S, Cerny T, Früh M.

Swiss Med Wkly. 2018 Dec 30;148:w14708. doi: 10.4414/smw.2018.14708. eCollection 2018 Dec 17.

20.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.

Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7.

21.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.

Diem S, Fässler M, Hasan Ali O, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L.

Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767. eCollection 2018.

22.

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

Griesinger F, Radke S, Lüers A, Deschler-Baier B, Kimmich M, Sebastian M, Schulz C, Brugger W, Wiewrodt R, Pirker R, Früh M, Gautschi O, Wolf J.

Pneumologie. 2018 Nov;72(11):774-781. doi: 10.1055/a-0647-9835. Epub 2018 Nov 8. German.

PMID:
30408830
23.

Multidisciplinary treatment of lung cancer in older patients: A review.

Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M, Putora PM.

J Geriatr Oncol. 2019 May;10(3):405-410. doi: 10.1016/j.jgo.2018.09.005. Epub 2018 Oct 3. Review.

PMID:
30292418
24.

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK).

J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.

PMID:
30267838
25.

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).

Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M.

Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832. doi: 10.1007/s00262-018-2239-4. Epub 2018 Aug 31.

PMID:
30171269
26.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

27.

Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study.

Leon-Reyes S, Schäfer J, Früh M, Schwenkglenks M, Reich O, Schmidlin K, Staehelin C, Battegay M, Cavassini M, Hasse B, Bernasconi E, Calmy A, Hoffmann M, Schoeni-Affolter F, Zhao H, Bucher HC.

Clin Infect Dis. 2019 Feb 15;68(5):827-833. doi: 10.1093/cid/ciy564.

28.

Immune checkpoint inhibitors and small cell lung cancer: what's new?

Schmid S, Früh M.

J Thorac Dis. 2018 May;10(Suppl 13):S1503-S1508. doi: 10.21037/jtd.2018.01.113. Review.

29.

The role of radiation therapy in the management of small cell lung cancer.

Glatzer M, Schmid S, Radovic M, Früh M, Putora PM.

Breathe (Sheff). 2017 Dec;13(4):e87-e94. doi: 10.1183/20734735.009617. Review.

30.

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Früh M, Peters S.

Cancer Cell. 2018 May 14;33(5):791-793. doi: 10.1016/j.ccell.2018.04.005.

31.

EML4-ALK Variant Affects ALK Resistance Mutations.

Früh M, Peters S.

J Clin Oncol. 2018 Apr 20;36(12):1257-1259. doi: 10.1200/JCO.2017.77.2764. Epub 2018 Mar 1. No abstract available.

PMID:
29494260
32.

Glucocorticoids and the Risk of Peptic Ulcer Bleeding: Case-Control Analysis Based on Swiss Claims Data.

Reinau D, Schwenkglenks M, Früh M, Signorell A, Blozik E, Meier CR.

Drug Saf. 2018 Jul;41(7):725-730. doi: 10.1007/s40264-018-0645-3.

PMID:
29468603
33.

Treatment of limited disease small cell lung cancer: the multidisciplinary team.

Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora PM.

Eur Respir J. 2017 Aug 24;50(2). pii: 1700422. doi: 10.1183/13993003.00422-2017. Print 2017 Aug. Review.

34.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

PMID:
28838390
35.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

36.

Inappropriate use of arthroscopic meniscal surgery in degenerative knee disease.

Muheim LLS, Senn O, Früh M, Reich O, Rosemann T, Neuner-Jehle SM.

Acta Orthop. 2017 Oct;88(5):550-555. doi: 10.1080/17453674.2017.1344915. Epub 2017 Jun 30.

37.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E.

J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13. Erratum in: J Clin Oncol. 2018 Mar 20;36(9):931.

38.

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.

Siano M, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V.

Oncologist. 2017 Jul;22(7):782-e70. doi: 10.1634/theoncologist.2017-0069. Epub 2017 Jun 7.

39.

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30.

PMID:
28557060
40.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

41.

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen S, Krähenbühl S, Kloft C, Joerger M.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19.

42.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
43.

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.

J Transl Med. 2017 Mar 30;15(1):66. doi: 10.1186/s12967-017-1174-z.

44.

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.

J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19.

45.

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L.

Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.

46.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
47.

SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer.

Putora PM, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M.

Oncol Res Treat. 2016;39(11):681-686. Epub 2016 Oct 19.

PMID:
27855379
49.

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, Cerny T, Joerger M.

Lung Cancer. 2016 Oct;100:38-44. doi: 10.1016/j.lungcan.2016.07.027. Epub 2016 Jul 28.

PMID:
27597279
50.

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M.

BMC Cancer. 2016 Aug 19;16:656. doi: 10.1186/s12885-016-2718-y.

Supplemental Content

Support Center